Trimethoprim and Histiocytosis haematophagic - a phase IV clinical study of FDA data

Summary:

Histiocytosis haematophagic is found among people who take Trimethoprim, especially for people who are male, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Trimethoprim and have Histiocytosis haematophagic. It is created by eHealthMe based on reports of 4,574 people who have side effects when taking Trimethoprim from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 30, 2022

4,574 people reported to have side effects when taking Trimethoprim.
Among them, 6 people (0.13%) have Histiocytosis haematophagic.


What is Trimethoprim?

Trimethoprim has active ingredients of trimethoprim. It is often used in urinary tract infection. eHealthMe is studying from 4,887 Trimethoprim users for its effectiveness, alternative drugs and more.

What is Histiocytosis haematophagic?

Histiocytosis haematophagic is found to be associated with 691 drugs and 557 conditions by eHealthMe.

Number of Trimethoprim and Histiocytosis haematophagic reports submitted per year:

Could Trimethoprim cause Histiocytosis haematophagic?

Time on Trimethoprim when people have Histiocytosis haematophagic *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Histiocytosis haematophagic when taking Trimethoprim *:

  • female: 16.67 %
  • male: 83.33 %

Age of people who have Histiocytosis haematophagic when taking Trimethoprim *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 50 %
  • 50-59: 0.0 %
  • 60+: 50 %

Common drugs people take besides Trimethoprim *:

  1. Fluconazole: 3 people, 50.00%
  2. Cyclophosphamide: 2 people, 33.33%
  3. Campath: 2 people, 33.33%
  4. Ramipril: 1 person, 16.67%
  5. Paracetamol: 1 person, 16.67%
  6. Omeprazole: 1 person, 16.67%
  7. Lactulose: 1 person, 16.67%
  8. Folotyn: 1 person, 16.67%
  9. Folic Acid: 1 person, 16.67%
  10. Famotidine: 1 person, 16.67%

Common side effects people have besides Histiocytosis haematophagic *:

  1. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 33.33%
  2. Fever: 2 people, 33.33%
  3. T-Cell Lymphoma Recurrent (reoccurs a blood cell cancer): 2 people, 33.33%
  4. Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 1 person, 16.67%
  5. Alanine Aminotransferase Increased: 1 person, 16.67%
  6. Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 16.67%
  7. Aspartate Aminotransferase Increased: 1 person, 16.67%
  8. Blood Alkaline Phosphatase Increased: 1 person, 16.67%
  9. Blood Bilirubin Increased: 1 person, 16.67%
  10. Blood Lactate Dehydrogenase Increased: 1 person, 16.67%

Common conditions people have *:

  1. T-Cell Lymphoma (a blood cell cancer): 2 people, 33.33%
  2. Osteoporosis (bones weak and more likely to break): 1 person, 16.67%
  3. Infusion Related Reaction: 1 person, 16.67%
  4. High Blood Pressure: 1 person, 16.67%
  5. High Blood Cholesterol: 1 person, 16.67%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 16.67%
  7. Constipation: 1 person, 16.67%
  8. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 16.67%
  9. Back Pain: 1 person, 16.67%
  10. Angioimmunoblastic T-Cell Lymphoma (mature t-cell cancer of the blood or lymph vessel): 1 person, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Trimethoprim and have Histiocytosis haematophagic?

Check whether Histiocytosis haematophagic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Trimethoprim:

Histiocytosis haematophagic treatments and more:

COVID vaccines that are related to Histiocytosis haematophagic:

How severe was Histiocytosis haematophagic and when was it recovered:

Expand to all the drugs that have ingredients of trimethoprim:

Common drugs associated with Histiocytosis haematophagic:

All the drugs that are associated with Histiocytosis haematophagic:

Common conditions associated with Histiocytosis haematophagic:

All the conditions that are associated with Histiocytosis haematophagic:

How the study uses the data?

The study uses data from the FDA. It is based on trimethoprim (the active ingredients of Trimethoprim) and Trimethoprim (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: